Ultrasound contrast developer Acusphere has secured $2.5 million in new debt financing.
The company currently is conducting a special protocol assessment with the U.S. Food and Drug Administration (FDA) for a phase III study of its Imagify ultrasound contrast agent.
The study will compare stress ultrasound with Imagify to unenhanced stress ultrasound for detecting coronary artery disease.
